Ahmedabad based Torrent Pharmaceuticals announced that it has entered into an agreement with Dr. Reddy's Laboratories Ltd. to acquire four of its brands "Styptovit-E", "Finast", "Finast-T", and "Dynapress".
Styptovit-E, a gynaecology product with an estimated market size of ~Rs. 500 crores (AIOCD data set), will further strengthen Torrent’s presence in the therapy. The acquisition of "Finast", "Finast-T", and "Dynapress", which are used in the treatment of Benign Prostatic Hyperplasia (BPH), will aid in Torrent's presence in the Urology therapy.
As per the terms of the definitive agreement, Torrent Pharma will take over the manufacturing, marketing and distribution of these brands in India. The complete integration and transition of the brands are expected to be completed by June 2022.
Torrent Pharma, with annual revenue of more than Rs. 8,500 crores, is the flagship Company of the Torrent Group, with group revenue of more than Rs. 20,000 crores. It is ranked 8th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI),Central Nervous System (CNS), and Vitamins Minerals Nutritionals (VMN).
